Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings

GlycoMimetics, Inc. (NASDAQ:GLYC) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for GlycoMimetics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the biotechnology company will earn ($0.03) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for GlycoMimetics’ current full-year earnings is ($0.08) per share.

Separately, Wall Street Zen began coverage on shares of GlycoMimetics in a research report on Saturday, May 17th. They issued a “sell” rating on the stock.

GlycoMimetics Trading Down 2.6%

Shares of GLYC stock opened at $0.17 on Wednesday. GlycoMimetics has a 12-month low of $0.14 and a 12-month high of $0.63. The firm’s 50 day moving average is $0.23 and its 200 day moving average is $0.25. The stock has a market capitalization of $10.71 million, a P/E ratio of -0.36 and a beta of 1.62.

Shares of GlycoMimetics are going to reverse split before the market opens on Monday, June 16th. The 1-100 reverse split was announced on Thursday, June 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, June 13th.

GlycoMimetics (NASDAQ:GLYC) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. bought a new stake in shares of GlycoMimetics during the 4th quarter valued at $1,268,000. VR Adviser LLC bought a new stake in shares of GlycoMimetics during the 4th quarter valued at $747,000. Wellington Management Group LLP bought a new stake in shares of GlycoMimetics during the 4th quarter valued at $352,000. Jefferies Financial Group Inc. bought a new stake in shares of GlycoMimetics during the 4th quarter valued at $106,000. Finally, ADAR1 Capital Management LLC raised its position in shares of GlycoMimetics by 626.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 286,127 shares during the period. 75.19% of the stock is currently owned by institutional investors.

About GlycoMimetics

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.